ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRAY
CUSIPN/A
Phone440-703-3210
Debt
Debt-to-Equity Ratio0.77
Current Ratio3.79
Quick Ratio3.04
Price-To-Earnings
Trailing P/E Ratio-6.80
Forward P/E Ratio-10.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$34.04 million
Price / Sales14.90
Cash FlowN/A
Price / CashN/A
Book Value$0.03 per share
Price / Book235.67
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-72,170,000.00
Net Margins-83.09%
Return on Equity-1,375.57%
Return on Assets-44.36%
Miscellaneous
Employees139
Outstanding Shares71,740,000
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) announced its quarterly earnings results on Thursday, May, 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $26.19 million for the quarter, compared to the consensus estimate of $15.50 million. Viewray had a negative return on equity of 1,375.57% and a negative net margin of 83.09%. The company's revenue for the quarter was up 2029.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.54) earnings per share. View Viewray's Earnings History.
What price target have analysts set for VRAY?
5 analysts have issued 1-year price objectives for Viewray's shares. Their forecasts range from $10.00 to $13.50. On average, they expect Viewray's share price to reach $11.90 in the next twelve months. View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Cantor Fitzgerald analysts commented, "Strong 1Q results. VRAY reported $26.2MM of revenue in 1Q, beating Street expectations by $13.1MM. Revenue was higher than expected due to delayed revenue recognition of a system installed in 4Q, earlier-than-expected recognition from an installation in late-1Q, and a system upgrade from the previous generation MRIdian Cobalt. VRAY placed four systems and upgraded one, which was in line with our expectations. VRAY received gross orders of $21MM, slightly below our expectation of $24MM. The backlog at the end of the quarter was $195MM, down slightly from $204MM last quarter." (5/11/2018)
- 2. Mizuho analysts commented, "We were at the Advanced Applications of MR-Guided Radiotherapy Symposium in Amsterdam on March 16th, 2018. The event was very well attended with approximately 200 people; most were potential customers who showed strong interest in ViewRay’s MRIdian. We highlight our key takeaways from the conference and additional insights into the MRI Linac below. Overall, we maintain our view that ViewRay has leadership in real time imaging guided LINAC today." (4/19/2018)
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), BioLife Solutions (BLFS), Second Sight Medical Products (EYES), Zynex Inc. common stock (ZYXI), Edap Tms (EDAP), Viveve Medical (VIVE), Semler Scientific (SMLR) and BioSig Technologies (BSGM).
When did Viewray IPO?
(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Has Viewray been receiving favorable news coverage?
Media stories about VRAY stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Viewray earned a media sentiment score of 0.07 on Accern's scale. They also gave news headlines about the company an impact score of 45.77 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Viewray's major shareholders?
Viewray's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fosun International Ltd (15.01%), Park West Asset Management LLC (4.80%), BlackRock Inc. (2.59%), Acuta Capital Partners LLC (2.58%), Next Century Growth Investors LLC (0.80%) and Russell Investments Group Ltd. (0.57%). Company insiders that own Viewray stock include Aditya Puri, Ajay Bansal, David P Bonita, Fmr Llc, Henry A Mckinnell and James F Dempsey. View Institutional Ownership Trends for Viewray.
Which institutional investors are selling Viewray stock?
VRAY stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Next Century Growth Investors LLC, Alpine Woods Capital Investors LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Viewray.
Which institutional investors are buying Viewray stock?
VRAY stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Park West Asset Management LLC, Millennium Management LLC, Thompson Siegel & Walmsley LLC, UBS Group AG, Russell Investments Group Ltd., Barclays PLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Viewray stock in the last two years include Aditya Puri, Ajay Bansal, David P Bonita and Henry A Mckinnell. View Insider Buying and Selling for Viewray.
How do I buy shares of Viewray?
Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of VRAY stock can currently be purchased for approximately $7.07.
How big of a company is Viewray?
Viewray has a market capitalization of $509.38 million and generates $34.04 million in revenue each year. The company earns $-72,170,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Viewray employs 139 workers across the globe.
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]
MarketBeat Community Rating for Viewray (VRAY)
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
